Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (IMPALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02702180
Recruitment Status : Completed
First Posted : March 8, 2016
Results First Posted : April 15, 2022
Last Update Posted : April 15, 2022
Sponsor:
Information provided by (Responsible Party):
Savara Inc.

Brief Summary:
This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor [rhGM-CSF]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.

Condition or disease Intervention/treatment Phase
Autoimmune Pulmonary Alveolar Proteinosis Drug: Molgramostim Drug: Placebo Device: PARI eFlow nebulizer system Phase 2

Detailed Description:

The trial is a phase 2, randomized, double-blind, placebo-controlled multicentre clinical trial investigating efficacy and safety of inhaled molgramostim (rhGM-CSF) in patients with aPAP.

The trial will include 2 periods; a double-blind treatment period consisting of up to 8 trial visits (Screening, Baseline, and at Weeks 4, 8,12, 16, 20 and 24 after randomisation) and a open-label follow-up period consisting of up to 5 trial visits (at Weeks 4, 12, 24, 36 and 48 post-treatment).

In the double-blind treatment period, eligible subjects will be randomised to treatment for up to 24 weeks with either: 1) inhaled molgramostim (300 µg) once daily (MOL-OD), 2) inhaled molgramostim (300 µg) and matching placebo administered intermittently (7 days on and 7 days off) (MOL-INT) or 3) inhaled placebo once daily (PBO). During the follow-up period, all participants will receive inhaled molgramostim intermittently (7 days on, 7 days off). During the trial, whole lung lavage (WLL) may be applied as rescue therapy in case of significant clinical worsening.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 139 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients
Actual Study Start Date : March 21, 2016
Actual Primary Completion Date : April 19, 2019
Actual Study Completion Date : September 27, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Double-blind molgramostim once daily
Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
Drug: Molgramostim
300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
Other Name: rhGM-CSF

Device: PARI eFlow nebulizer system
PARI eFlow nebulizer system

Experimental: Double-blind molgramostim intermittent
Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
Drug: Molgramostim
300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
Other Name: rhGM-CSF

Device: PARI eFlow nebulizer system
PARI eFlow nebulizer system

Placebo Comparator: Double-blind placebo
Inhalation of placebo nebuliser solution once daily for 24 weeks
Drug: Placebo
Placebo nebulizer solution for inhalation

Device: PARI eFlow nebulizer system
PARI eFlow nebulizer system

Experimental: Open-label molgramostim intermittent
Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period
Drug: Molgramostim
300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
Other Name: rhGM-CSF

Device: PARI eFlow nebulizer system
PARI eFlow nebulizer system




Primary Outcome Measures :
  1. Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]
    Measurement of (A-a)DO2 was done by blood gas analysis. An arterial blood sample was collected in the supine position, after resting for at least 10 minutes (or longer if required to achieve stable oxygen saturation). The sample was analyzed for arterial oxygen tension (PaO2) and partial pressure of carbon dioxide (PaCO2). The calculation of (A-a)DO2 was done centrally by using a formula described in the protocol.


Secondary Outcome Measures :
  1. Change From Baseline in 6-minute Walking Distance (6MWD) After 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]

    The 6MWD was assessed by the use of 6-minute walking test (6MWT). The 6MWT was performed in accordance with the 2014 ATS/ERS guideline "field walking tests in chronic respiratory disease" (Holland et al. 2014) by technicians with documented training and experience.

    Where possible, the test was conducted with the participant breathing ambient atmospheric air. If the participant required oxygen supplementation at rest, a titration procedure was carried out as part of the 6MWT at screening in order to determine the oxygen flow rate required for the participant to complete the test. This flow rate was to be used during subsequent tests, if possible.


  2. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score After 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]
    The SGRQ is designed to measure health impairment in patients with asthma and chronic obstructive pulmonary disease (COPD). It consists of two parts, where Part 1 covers the participants' recollection of their symptoms over the preceding period (1 month recall used in this trial, Symptoms component) and Part 2 addresses the participants' current state in terms of disturbances to their daily physical activity (Activity component) and a wide range of disturbances of psycho-social function (Impact component). A total score as well as individual component scores were calculated. Scores (total and component) range from 0 to 100, with higher scores indicating more limitations.

  3. Number of Whole Lung Lavage During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]

    In all versions of the protocol (no participants were recruited under version 1.0), whole lung lavage (single lung or both lungs) was applied as rescue therapy. In protocol version 2.0, the criterion for performing whole lung lavage was an increase in (A-a)DO2 by more than 10 mmHg/1.33 kilopascal compared to baseline. In protocol version 3.0 onwards, the criterion for performing whole lung lavage was clinical worsening of aPAP based on symptoms, reduced exercise capacity and/or findings of hypoxemia or desaturation according to the investigator's judgement.

    In protocol versions 2.0 and 3.0, participants undergoing whole lung lavage during the double-blind period were to discontinue double-blind treatment, encouraged to continue to follow the same visit schedule and, if required, receive further whole lung lavage at the investigator's discretion. In protocol version 4.0 and 5.0, participants undergoing whole lung lavage were to continue double-blind treatment.


  4. Number of Adverse Events (AEs) During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]

    Treatment-emergent adverse events (AEs) were assessed on or after the first dose of trial drug to 28 days after last dose.

    Information about AEs was collected by the investigator by a non-leading question such as "have you experienced any new health problems or worsening of existing conditions" and by reporting events directly observed or spontaneously volunteered by participants (e.g., in the Subject Diary Card, where subjects were asked to record any AEs and answer questions regarding lung toxicity and known systemic effects). Participants were also encouraged to contact the clinic in between visits if they experienced AEs or had any concerns.

    All AEs were assessed by the investigator for severity (mild, moderate, severe), outcome (recovered, not recovered, recovered with sequelae, fatal, unknown) and causality (unlikely, possible, probable, not applicable) according to current regulatory standards.


  5. Number of Serious Adverse Events (SAEs) During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]

    SAEs are defined as any untoward medicinal occurrence or effect that at any dose:

    • Results in death
    • Is life-threatening
    • Requires hospitalisation or prolongation of existing hospitalisation
    • Results in persistent or significant disability or incapacity
    • Is a congenital anomaly or birth defect
    • May jeopardise the subject or may require intervention to prevent one or more of the other outcomes listed above (Important Medical Events)

  6. Number of Adverse Drug Reactions (ADRs) During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]
    All AEs judged by either the reporting investigator or the sponsor as having a reasonable causal relationship to a medicinal product qualify as ADRs. The expression reasonable causal relationship means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility i.e. the relationship cannot be ruled out.

  7. Number of Severe AEs During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]

    All AEs were assessed by the investigator for severity (mild, moderate, severe) according to current regulatory standards:

    • Mild: The AE is easily tolerated and does not interfere with daily activity.
    • Moderate: The AE interferes with daily activity, but the subject is still able to function. Medical intervention may be considered.
    • Severe: The AE is incapacitating and requires medical intervention.

  8. Number of Participants With at Least 1 AE Leading to Treatment Discontinuation During 24 Weeks of Treatment [ Time Frame: From baseline to 24 weeks ]
    Participants could be discontinued from treatment and assessments at any time, if deemed necessary by the investigator. Potential reasons for discontinuation of treatment included e.g. unacceptable AE.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aPAP diagnosed by computed tomography, or by biopsy, or by Broncho Alveolar Lavage (BAL), and by increased GM-CSF autoantibodies in serum.
  • Stable or progressive aPAP during a minimum period of 2 months prior to the Baseline visit.
  • Arterial oxygen tension (PaO2) <75 mmHg/<10 kilo Pascal (kPa) at rest, OR desaturation of >4 percentage points on the 6MWT
  • An alveolar-arterial oxygen difference [(A-a)DO2] of minimum 25 mmHg/3.33 kPa
  • Female or male ≥18 years of age
  • Females who have been post-menopausal for >1 year or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence), during and until 30 days after last dose of double-blind trial treatment. Females of childbearing potential must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at dosing at Baseline (Visit 2) and must not be lactating
  • Males agreeing to use condoms during and until 30 days after last dose of double-blind medication, or males having a female partner who is using adequate contraception as described above
  • Willing and able to provide signed informed consent
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the investigator

Exclusion Criteria:

  • Diagnosis of hereditary or secondary PAP
  • WLL within 1 month of Baseline
  • Treatment with GM-CSF within 3 months of Baseline
  • Treatment with rituximab within 6 months of Baseline
  • Treatment with plasmapheresis within 3 months of Baseline
  • Treatment with any investigational medicinal product within 4 weeks of Screening
  • Concomitant use of sputum modifying drugs such as carbocysteine or ambroxol
  • History of allergic reactions to GM-CSF
  • Connective tissue disease, inflammatory bowel disease or other autoimmune disorder requiring treatment associated with significant immunosuppression, e.g. more than 10 mg/day systemic prednisolone
  • Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product
  • History of, or present, myeloproliferative disease or leukaemia
  • Known active infection (viral, bacterial, fungal or mycobacterial)
  • Apparent pre-existing concurrent pulmonary fibrosis
  • Any other serious medical condition which in the opinion of the investigator would make the participant unsuitable for the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02702180


Locations
Show Show 30 study locations
Sponsors and Collaborators
Savara Inc.
Investigators
Layout table for investigator information
Principal Investigator: Cliff Morgan, MD Royal Brompton Hospital London
  Study Documents (Full-Text)

Documents provided by Savara Inc.:
Study Protocol  [PDF] December 1, 2017
Statistical Analysis Plan  [PDF] April 25, 2019

Publications:
Layout table for additonal information
Responsible Party: Savara Inc.
ClinicalTrials.gov Identifier: NCT02702180    
Other Study ID Numbers: MOL-PAP-002
2015-003878-33 ( EudraCT Number )
First Posted: March 8, 2016    Key Record Dates
Results First Posted: April 15, 2022
Last Update Posted: April 15, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Alveolar Proteinosis
Autoimmune Diseases
Lung Diseases
Respiratory Tract Diseases
Immune System Diseases
Molgramostim
Sargramostim
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs